BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, El-Khoueiry A, Feng M, Katz MHG, Primrose J, Soares HP, Valle J, Maithel SK. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37:1015-1027. [PMID: 30856044 DOI: 10.1200/jco.18.02178] [Cited by in Crossref: 113] [Cited by in F6Publishing: 47] [Article Influence: 37.7] [Reference Citation Analysis]
Number Citing Articles
1 Ren B, Guo Q, Yang Y, Liu L, Wei S, Chen W, Tian Y. A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma. Radiat Oncol 2020;15:15. [PMID: 31941520 DOI: 10.1186/s13014-020-1459-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
2 Okusaka T. Cholangiocarcinoma: is it time for a revolution? Expert Rev Gastroenterol Hepatol 2021;15:467-70. [PMID: 33840344 DOI: 10.1080/17474124.2021.1915766] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Marcus R, Ferri-Borgogno S, Hosein A, Foo WC, Ghosh B, Zhao J, Rajapakshe K, Brugarolas J, Maitra A, Gupta S. Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:5709. [PMID: 34830866 DOI: 10.3390/cancers13225709] [Reference Citation Analysis]
4 Heinrich S, Watzka F, Lang H. Integrative Concepts for Liver Surgery. Visc Med 2020;36:351-8. [PMID: 33178731 DOI: 10.1159/000511043] [Reference Citation Analysis]
5 Oh MY, Kim H, Choi YJ, Byun Y, Han Y, Kang JS, Sohn H, Lee JM, Kwon W, Jang JY. Conversion surgery for initially unresectable extrahepatic biliary tract cancer. Ann Hepatobiliary Pancreat Surg 2021;25:349-57. [PMID: 34402435 DOI: 10.14701/ahbps.2021.25.3.349] [Reference Citation Analysis]
6 Fragkou N, Sideras L, Panas P, Emmanouilides C, Sinakos E. Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence? World J Gastroenterol 2021; 27(27): 4252-4275 [PMID: 34366604 DOI: 10.3748/wjg.v27.i27.4252] [Reference Citation Analysis]
7 Wang L, Deng M, Ke Q, Lou J, Zheng S, Bi X, Wang J, Guo W, Li F, Wang J, Zheng Y, Li J, Cheng S, Zhou W, Zeng Y. Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study. Cancer Med 2020;9:2674-85. [PMID: 32072774 DOI: 10.1002/cam4.2925] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Wang G, Wang Q, Fan X, Ding L, Dong L. The Significance of Adjuvant Therapy for Extrahepatic Cholangiocarcinoma After Surgery. Cancer Manag Res 2019;11:10871-82. [PMID: 31920396 DOI: 10.2147/CMAR.S224583] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
9 Coimbra FJF, Torres OJM, Alikhanov R, Agarwal A, Pessaux P, Fernandes ESM, Quireze-Junior C, Araujo RLC, Godoy AL, Waechter FL, Resende AP, Boff MF, Coelho GR, Rezende MB, Linhares MM, Belotto M, Moraes-Junior JMA, Amaral PCG, Pinto RD, Genzini T, Lima AS, Ribeiro HSC, Ramos EJ, Anghinoni M, Pereira LL, Enne M, Sampaio A, Montagnini AL, Diniz A, Jesus VHF, Sirohi B, Shrikhande SV, Peixoto RDA, Kalil AN, Jarufe N, Smith M, Herman P; Grupo Internacional de Estudos de Câncer Hepatopancreatobiliar - ISG-HPB-Cancer. BRAZILIAN CONSENSUS ON INCIDENTAL GALLBLADDER CARCINOMA. Arq Bras Cir Dig 2020;33:e1496. [PMID: 32667526 DOI: 10.1590/0102-672020190001e1496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
10 Ke Q, Wang B, Lin N, Wang L, Liu J. Does high-grade dysplasia/carcinoma in situ of the biliary duct margin affect the prognosis of extrahepatic cholangiocarcinoma? A meta-analysis. World J Surg Oncol 2019;17:211. [PMID: 31818290 DOI: 10.1186/s12957-019-1749-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Sposito C, Droz Dit Busset M, Virdis M, Citterio D, Flores M, Bongini M, Niger M, Mazzaferro V. The role of lymphadenectomy in the surgical treatment of intrahepatic cholangiocarcinoma: A review. Eur J Surg Oncol 2021:S0748-7983(21)00679-X. [PMID: 34412956 DOI: 10.1016/j.ejso.2021.08.009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Rizzo A, Ricci AD, Brandi G. Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand? Expert Review of Precision Medicine and Drug Development 2021;6:217-24. [DOI: 10.1080/23808993.2021.1915126] [Reference Citation Analysis]
13 Jethwa KR, Sannapaneni S, Mullikin TC, Harmsen WS, Petersen MM, Antharam P, Laughlin B, Mahipal A, Halfdanarson TR, Merrell KW, Neben-Wittich M, Sio TT, Haddock MG, Hallemeier CL. Chemoradiotherapy for patients with locally advanced or unresectable extra-hepatic biliary cancer. J Gastrointest Oncol. 2020;11:1408-1420. [PMID: 33457010 DOI: 10.21037/jgo-20-245] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Thornblade LW, Wong P, Li D, Warner SG, Chang S, Raoof M, Kessler J, Amini A, Lin J, Chung V, Singh G, Fong Y, Melstrom LG. Patterns of Whole Exome Sequencing in Resected Cholangiocarcinoma. Cancers (Basel) 2021;13:4062. [PMID: 34439216 DOI: 10.3390/cancers13164062] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Namjan A, Techasen A, Loilome W, Sa-Ngaimwibool P, Jusakul A. ARID1A alterations and their clinical significance in cholangiocarcinoma. PeerJ 2020;8:e10464. [PMID: 33344089 DOI: 10.7717/peerj.10464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Dee EC, Freret ME, Horick N, Raldow AC, Goyal L, Zhu AX, Parikh AR, Ryan DP, Clark JW, Allen JN, Ferrone CR, Fernandez-Del Castillo C, Tanabe KK, Drapek LC, Hong TS, Qadan M, Wo JY. Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. Ann Surg Oncol 2020;27:5161-72. [PMID: 32740733 DOI: 10.1245/s10434-020-08967-9] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Turgeon MK, Maithel SK. Cholangiocarcinoma: a site-specific update on the current state of surgical management and multi-modality therapy. Chin Clin Oncol 2020;9:4. [PMID: 31500433 DOI: 10.21037/cco.2019.08.09] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
18 Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557-588. [PMID: 32606456 DOI: 10.1038/s41575-020-0310-z] [Cited by in Crossref: 160] [Cited by in F6Publishing: 167] [Article Influence: 80.0] [Reference Citation Analysis]
19 Krenzien F, Nevermann N, Krombholz A, Benzing C, Haber P, Fehrenbach U, Lurje G, Pelzer U, Pratschke J, Schmelzle M, Schöning W. Treatment of Intrahepatic Cholangiocarcinoma-A Multidisciplinary Approach. Cancers (Basel) 2022;14:362. [PMID: 35053523 DOI: 10.3390/cancers14020362] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Xu S, Zhang XP, Zhao GD, Zhao ZM, Gao YX, Hu MG, Tan XL, Liu R. Development and validation of an online calculator to predict early recurrence and long-term survival in patients with distal cholangiocarcinoma after pancreaticoduodenectomy. J Hepatobiliary Pancreat Sci 2021. [PMID: 34676993 DOI: 10.1002/jhbp.1058] [Reference Citation Analysis]
21 Balasubramanian B, Venkatraman S, Myint KZ, Janvilisri T, Wongprasert K, Kumkate S, Bates DO, Tohtong R. Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma. Pharmaceuticals (Basel) 2021;14:51. [PMID: 33440754 DOI: 10.3390/ph14010051] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Spolverato G, Glavas D, Hewitt DB, Brown ZJ, Capelli G, Bergamo F, Rizzato MD, Pawlik TM. Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs. Expert Opin Pharmacother 2021;:1-9. [PMID: 34964678 DOI: 10.1080/14656566.2021.2020250] [Reference Citation Analysis]
23 Gravely AK, Vibert E, Sapisochin G. Surgical treatment of intrahepatic cholangiocarcinoma. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.004] [Reference Citation Analysis]
24 Zhao J, Zhang W, Zhang J, Chen YT, Ma WJ, Liu SY, Li FY, Song B. Independent Risk Factors of Early Recurrence After Curative Resection for Perihilar Cholangiocarcinoma: Adjuvant Chemotherapy May Be Beneficial in Early Recurrence Subgroup. Cancer Manag Res 2020;12:13111-23. [PMID: 33376403 DOI: 10.2147/CMAR.S289094] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Watanabe J, Matsui R, Sasanuma H, Ishizaki Y, Fukunaga T, Kotani K, Sata N. Body composition assessment and sarcopenia in patients with biliary tract cancer: A systematic review and meta-analysis. Clin Nutr 2021;41:321-8. [PMID: 34999326 DOI: 10.1016/j.clnu.2021.12.005] [Reference Citation Analysis]
26 Wada Y, Shimada M, Yamamura K, Toshima T, Banwait JK, Morine Y, Ikemoto T, Saito Y, Baba H, Mori M, Goel A. A Transcriptomic Signature for Risk-Stratification and Recurrence Prediction in Intrahepatic Cholangiocarcinoma. Hepatology 2021;74:1371-83. [PMID: 33725402 DOI: 10.1002/hep.31803] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
27 Yoo C, Shin SH, Park JO, Kim KP, Jeong JH, Ryoo BY, Lee W, Song KB, Hwang DW, Park JH, Lee JH. Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review. Cancers (Basel) 2021;13:1647. [PMID: 33916008 DOI: 10.3390/cancers13071647] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
28 Kim K, Yu JI, Jung W, Kim TH, Seong J, Kim WC, Choi JH, Park Y, Jeong BK, Kim BH, Kim TG, Kim JH, Park HJ, Shin HS, Im JH, Heo JS, Park JO, Jang JY, Oh DY, Woo SM, Lee WJ, Chie EK. Role of adjuvant radiotherapy in extrahepatic bile duct cancer: A multicenter retrospective study (Korean Radiation Oncology Group 18-14). Eur J Cancer 2021;157:31-9. [PMID: 34474218 DOI: 10.1016/j.ejca.2021.07.045] [Reference Citation Analysis]
29 Utuama O, Permuth JB, Dagne G, Sanchez-Anguiano A, Alman A, Kumar A, Denbo J, Kim R, Fleming JB, Anaya DA. Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: A Propensity Score Survival Analysis Supporting Use in Patients with High-Risk Disease. Ann Surg Oncol 2021;28:1939-49. [PMID: 33415559 DOI: 10.1245/s10434-020-09478-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
30 Zhu J, Wu Y, Xiao W, Li Y. Survival Predictors of Resectable Gallbladder Carcinoma: An Analysis of the Surveillance, Epidemiology, and End Results Database. The American Surgeon. [DOI: 10.1177/00031348221074238] [Reference Citation Analysis]
31 Lai Q, Mennini G, Larghi Laureiro Z, Rossi M. Uncommon indications for associating liver partition and portal vein ligation for staged hepatectomy: a systematic review. Hepatobiliary Surg Nutr 2021;10:210-25. [PMID: 33898561 DOI: 10.21037/hbsn-20-355] [Reference Citation Analysis]
32 Zaidi MY, Abou-Alfa GK, Ethun CG, Shrikhande SV, Goel M, Nervi B, Primrose J, Valle JW, Maithel SK. Evaluation and management of incidental gallbladder cancer. Chin Clin Oncol 2019;8:37. [PMID: 31431030 DOI: 10.21037/cco.2019.07.01] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
33 Sugiura T, Uesaka K, Okamura Y, Ito T, Yamamoto Y, Ashida R, Ohgi K, Asakura H, Todaka A, Fukutomi A. Adjuvant chemoradiotherapy for positive hepatic ductal margin on cholangiocarcinoma. Ann Gastroenterol Surg 2020;4:455-63. [PMID: 32724890 DOI: 10.1002/ags3.12345] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Keilson JM, Maithel SK. The Undertreatment of Gallbladder Cancer: Gaps in Seeking, Reaching, and Receiving Care. Ann Surg Oncol 2021;28:2925-7. [PMID: 33661462 DOI: 10.1245/s10434-021-09761-x] [Reference Citation Analysis]
35 Shulman RM, Meyer JE. Patterns of Failure and Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. Ann Surg Oncol 2020;27:4867-9. [PMID: 32804323 DOI: 10.1245/s10434-020-09014-3] [Reference Citation Analysis]
36 Juratli MA, Struecker B, Katou S, Morguel MH, Pascher A. [Influence of molecular pathology on oncological surgery of liver and bile duct tumors]. Chirurg 2021;92:1003-10. [PMID: 34519849 DOI: 10.1007/s00104-021-01495-6] [Reference Citation Analysis]
37 Zlobec I, Berger MD, Lugli A. Tumour budding and its clinical implications in gastrointestinal cancers. Br J Cancer 2020;123:700-8. [PMID: 32601463 DOI: 10.1038/s41416-020-0954-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
38 Makiuchi T, Sobue T. Descriptive epidemiology of biliary tract cancer incidence and geographic variation in Japan. Eur J Cancer Prev 2022. [PMID: 35485392 DOI: 10.1097/CEJ.0000000000000758] [Reference Citation Analysis]
39 Gutiérrez-Larrañaga M, González-López E, Roa-Bautista A, Rodrigues PM, Díaz-González Á, Banales JM, López-Hoyos M, Santos-Laso A, Crespo J. Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy? Liver Cancer 2021;10:545-60. [PMID: 34950178 DOI: 10.1159/000518104] [Reference Citation Analysis]
40 Lamarca A, Kapacee Z, Breeze M, Bell C, Belcher D, Staiger H, Taylor C, McNamara MG, Hubner RA, Valle JW. Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers.J Clin Med. 2020;9. [PMID: 32899345 DOI: 10.3390/jcm9092854] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
41 Dee EC, Freret ME, Wo JY. ASO Author Reflections: Adjuvant Chemoradiation for Patients with Resected Biliary Tract Cancers. Ann Surg Oncol 2020;27:5173-4. [PMID: 32748150 DOI: 10.1245/s10434-020-08970-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Lamarca A, Edeline J, Goyal L. How I treat biliary tract cancer. ESMO Open 2022;7:100378. [PMID: 35032765 DOI: 10.1016/j.esmoop.2021.100378] [Reference Citation Analysis]
43 de Jong EJM, Mommers I, Fariña Sarasqueta A, van der Geest LG, Heij L, de Hingh IHJT, Homs MYV, Tjan-Heijnen VCG, Valkenburg-van Iersel LBJ, Wilmink JW, Geurts SME, de Vos-Geelen J; Dutch Pancreatic Cancer Group. Adjuvant and first-line palliative chemotherapy regimens in patients diagnosed with periampullary cancer: a short report from a nationwide registry. Acta Oncol 2022;61:591-6. [PMID: 35382678 DOI: 10.1080/0284186X.2022.2053199] [Reference Citation Analysis]
44 Yang Y, Zou X, Zhou W, Yuan G, Hu D, Shen Y, Xie Q, Zhang Q, Kuang D, Hu X, Li Z. DWI-based radiomic signature: potential role for individualized adjuvant chemotherapy in intrahepatic cholangiocarcinoma after partial hepatectomy. Insights Imaging 2022;13:37. [PMID: 35244793 DOI: 10.1186/s13244-022-01179-7] [Reference Citation Analysis]
45 Personeni N, Lleo A, Pressiani T, Colapietro F, Openshaw MR, Stavraka C, Pouptsis A, Pinato DJ, Rimassa L. Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. Cancers (Basel) 2020;12:E3370. [PMID: 33202975 DOI: 10.3390/cancers12113370] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
46 Sasaki T, Takeda T, Okamoto T, Ozaka M, Sasahira N. Chemotherapy for Biliary Tract Cancer in 2021. J Clin Med 2021;10:3108. [PMID: 34300274 DOI: 10.3390/jcm10143108] [Reference Citation Analysis]
47 de Savornin Lohman E, Duijster J, Groot Koerkamp B, van der Post R, Franz E, Mughini Gras L, de Reuver P. Severe Salmonella spp. or Campylobacter spp. Infection and the Risk of Biliary Tract Cancer: A Population-Based Study. Cancers (Basel) 2020;12:E3348. [PMID: 33198229 DOI: 10.3390/cancers12113348] [Reference Citation Analysis]
48 Li Q, Chen C, Su J, Qiu Y, Wu H, Song T, Mao X, He Y, Cheng Z, Li J, Zhai W, Zhang D, Geng Z, Tang Z. Recurrence and prognosis in intrahepatic cholangiocarcinoma patients with different etiology after radical resection: a multi-institutional study. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09448-w] [Reference Citation Analysis]
49 Mohr R, Özdirik B, Knorr J, Wree A, Demir M, Tacke F, Roderburg C. In Vivo Models for Cholangiocarcinoma-What Can We Learn for Human Disease? Int J Mol Sci 2020;21:E4993. [PMID: 32679791 DOI: 10.3390/ijms21144993] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
50 Cloyd JM, Ejaz A, Pawlik TM. The Landmark Series: Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2020;27:2859-2865. [PMID: 32419038 DOI: 10.1245/s10434-020-08621-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
51 Zhang Z, Wang Z, Huang Y. A Bibliometric Analysis of 8,276 Publications During the Past 25 Years on Cholangiocarcinoma by Machine Learning. Front Oncol 2021;11:687904. [PMID: 34557406 DOI: 10.3389/fonc.2021.687904] [Reference Citation Analysis]
52 Soares KC, Jarnagin WR. The Landmark Series: Hilar Cholangiocarcinoma. Ann Surg Oncol 2021;28:4158-70. [PMID: 33829358 DOI: 10.1245/s10434-021-09871-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Ke Q, Lin N, Deng M, Wang L, Zeng Y, Liu J. The effect of adjuvant therapy for patients with intrahepatic cholangiocarcinoma after surgical resection: A systematic review and meta-analysis. PLoS One. 2020;15:e0229292. [PMID: 32084210 DOI: 10.1371/journal.pone.0229292] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
54 Turkes F, Carmichael J, Cunningham D, Starling N. Contemporary Tailored Oncology Treatment of Biliary Tract Cancers. Gastroenterol Res Pract 2019;2019:7698786. [PMID: 31929787 DOI: 10.1155/2019/7698786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
55 Zori AG, Yang D, Draganov PV, Cabrera R. Advances in the management of cholangiocarcinoma. World J Hepatol 2021; 13(9): 1003-1018 [PMID: 34630871 DOI: 10.4254/wjh.v13.i9.1003] [Reference Citation Analysis]
56 Cloyd JM, Pawlik TM. Trends in the use of adjuvant therapy for resected intrahepatic cholangiocarcinoma: getting ahead of the data. Hepatobiliary Surg Nutr 2021;10:515-7. [PMID: 34430532 DOI: 10.21037/hbsn-2021-12] [Reference Citation Analysis]
57 Oneda E, Abu Hilal M, Zaniboni A. Biliary Tract Cancer: Current Medical Treatment Strategies.Cancers (Basel). 2020;12. [PMID: 32423017 DOI: 10.3390/cancers12051237] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
58 Fiste O, Ntanasis-Stathopoulos I, Gavriatopoulou M, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F. The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. Vaccines (Basel) 2021;9:422. [PMID: 33922362 DOI: 10.3390/vaccines9050422] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Hara Y, Yamamura K, Matsumura K, Oda E, Akahoshi S, Yuki H, Tomiguchi J, Motohara T, Miyamoto H, Komohara Y, Beppu T. Laparoscopic Surgery for a Patient With Multiple Liver Metastases of Unknown Origin Concomitant With Gallbladder Tumor. In Vivo 2021;35:2963-8. [PMID: 34410995 DOI: 10.21873/invivo.12590] [Reference Citation Analysis]
60 Mao J, Yang X, Lin J, Yang X, Wang D, Zhang L, Bai Y, Bian J, Long J, Xie F, Huang H, Sang X, Chen S, Zhao H. Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma. J Cancer 2021;12:1555-62. [PMID: 33532001 DOI: 10.7150/jca.53482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Hamura R, Haruki K, Taniai T, Yanagaki M, Shirai Y, Furukawa K, Usuba T, Fujioka S, Okamoto T, Nakabayashi Y, Uwagawa T, Ikegami T. The impact of S-1 for the patient with lymph nodal metastasis biliary tract cancer as adjuvant chemotherapy: a multicenter database analysis. Int J Clin Oncol. [DOI: 10.1007/s10147-022-02165-1] [Reference Citation Analysis]
62 Gamboa AC, Maithel SK. The Landmark Series: Gallbladder Cancer. Ann Surg Oncol 2020;27:2846-58. [PMID: 32474816 DOI: 10.1245/s10434-020-08654-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
63 Choi SH, Rim CH, Shin IS, Yoon WS, Koom WS, Seong J. Adjuvant Radiotherapy for Extrahepatic Cholangiocarcinoma: A Quality Assessment-Based Meta-Analysis. Liver Cancer 2021;10:419-32. [PMID: 34721505 DOI: 10.1159/000518298] [Reference Citation Analysis]
64 Gringeri E, Gambato M, Sapisochin G, Ivanics T, Lynch EN, Mescoli C, Burra P, Cillo U, Russo FP. Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology. J Clin Med 2020;9:E1353. [PMID: 32380750 DOI: 10.3390/jcm9051353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
65 Medin CR, Maithel SK. Neoadjuvant therapy trials in biliary tract malignancies. J Surg Oncol 2022;125:84-8. [PMID: 34897705 DOI: 10.1002/jso.26714] [Reference Citation Analysis]
66 Fong ZV, Brownlee SA, Qadan M, Tanabe KK. The Clinical Management of Cholangiocarcinoma in the United States and Europe: A Comprehensive and Evidence-Based Comparison of Guidelines. Ann Surg Oncol 2021;28:2660-74. [PMID: 33646431 DOI: 10.1245/s10434-021-09671-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
67 Panayotova G, Guerra J, Guarrera JV, Lunsford KE. The Role of Surgical Resection and Liver Transplantation for the Treatment of Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2428. [PMID: 34070772 DOI: 10.3390/jcm10112428] [Reference Citation Analysis]
68 Ji GW, Wang K, Xia YX, Wang JS, Wang XH, Li XC. Integrating Machine Learning and Tumor Immune Signature to Predict Oncologic Outcomes in Resected Biliary Tract Cancer. Ann Surg Oncol 2021;28:4018-29. [PMID: 33230745 DOI: 10.1245/s10434-020-09374-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
69 Washington K, Rocha F. Approach to Resectable Biliary Cancers. Curr Treat Options Oncol 2021;22:97. [PMID: 34524554 DOI: 10.1007/s11864-021-00896-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Hao D, Zhang Z, Ji Y. Responsive polymeric drug delivery systems for combination anticancer therapy: experimental design and computational insights. International Journal of Polymeric Materials and Polymeric Biomaterials. [DOI: 10.1080/00914037.2021.1960340] [Reference Citation Analysis]
71 Czauderna C, Kirstein MM, Tews HC, Vogel A, Marquardt JU. Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2803. [PMID: 34202401 DOI: 10.3390/jcm10132803] [Reference Citation Analysis]
72 Beetz O, Weigle CA, Cammann S, Vondran FWR, Timrott K, Kulik U, Bektas H, Klempnauer J, Kleine M, Oldhafer F. Preoperative leukocytosis and the resection severity index are independent risk factors for survival in patients with intrahepatic cholangiocarcinoma. Langenbecks Arch Surg 2020;405:977-88. [PMID: 32815017 DOI: 10.1007/s00423-020-01962-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
73 Lamarca A, Gambardella V, Cejalvo JM, Fleitas-Kanonnikoff T, Cervantes A. In the literature: June 2019. ESMO Open 2019;4:e000547. [PMID: 31297241 DOI: 10.1136/esmoopen-2019-000547] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
74 Ke Q, Wang L, Lin Z, Lou J, Zheng S, Bi X, Wang J, Guo W, Li F, Wang J, Zheng Y, Li J, Cheng S, Zhou W, Zeng Y. Prognostic Value of Lymph Node Dissection for Intrahepatic Cholangiocarcinoma Patients With Clinically Negative Lymph Node Metastasis: A Multi-Center Study From China. Front Oncol 2021;11:585808. [PMID: 33777738 DOI: 10.3389/fonc.2021.585808] [Reference Citation Analysis]
75 Zhao J, Chen Y, Wang J, Wang J, Wang Y, Chai S, Zhang Y, Chen X, Zhang W. Preoperative risk grade predicts the long-term prognosis of intrahepatic cholangiocarcinoma: a retrospective cohort analysis. BMC Surg 2021;21:113. [PMID: 33676467 DOI: 10.1186/s12893-020-00954-x] [Reference Citation Analysis]
76 Xu S, Zhang XP, Zhao GD, Zou WB, Zhao ZM, Hu MG, Gao YX, Tan XL, Liu Q, Liu R. A novel online calculator to predict recurrence risk in patients with distal cholangiocarcinoma after radical pancreaticoduodenectomy. J Surg Oncol 2021. [PMID: 34617593 DOI: 10.1002/jso.26709] [Reference Citation Analysis]
77 Uson Junior PLS, DeLeon TT, Bogenberger JM, Pai RK, Kosiorek HE, Yin J, Ahn DH, Sonbol MB, Bekaii-Saab T, Mansfield AS, Buetow K, Gores GJ, Smoot R, Vasmatzis G, Kipp BR, Mahipal A, Baker AT, Babiker H, Barro O, Dumbauld C, Zhou Y, Aslam FN, Barrett M, Jacobs B, Meurice N, Arora M, Petit J, Elliott N, Nagalo B, Salomao MA, Borad MJ. FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. Dig Dis Sci 2021. [PMID: 34773565 DOI: 10.1007/s10620-021-07303-9] [Reference Citation Analysis]
78 Wada Y, Shimada M, Morine Y, Ikemoto T, Saito Y, Baba H, Mori M, Goel A. A blood-based noninvasive miRNA signature for predicting survival outcomes in patients with intrahepatic cholangiocarcinoma. Br J Cancer 2022. [PMID: 35079106 DOI: 10.1038/s41416-022-01710-z] [Reference Citation Analysis]
79 Jayaraman P, Gaston K. Targeting protein kinase CK2 in the treatment of cholangiocarcinoma. Exploration of Targeted Anti-tumor Therapy 2021;2. [DOI: 10.37349/etat.2021.00055] [Reference Citation Analysis]
80 Naveed S, Qari H, Thau CM, Burasakarn P, Mir AW. Neoadjuvant Chemotherapy for Advanced Gallbladder Cancer: Do We have Enough Evidence? A Systematic Review. Euroasian J Hepatogastroenterol 2021;11:87-94. [PMID: 34786362 DOI: 10.5005/jp-journals-10018-1348] [Reference Citation Analysis]
81 Kankeu Fonkoua LA, Serrano Uson Junior PL, Mody K, Mahipal A, Borad MJ, Roberts LR. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications. Expert Opin Ther Targets 2022. [PMID: 35034558 DOI: 10.1080/14728222.2022.2029412] [Reference Citation Analysis]
82 Edeline J, Hirano S, Bertaut A, Konishi M, Benabdelghani M, Uesaka K, Watelet J, Ohtsuka M, Hammel P, Kaneoka Y, Joly JP, Yamamoto M, Monard L, Ambo Y, Louvet C, Ando M, Malka D, Nagino M, Phelip JM, Ebata T. Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies. Eur J Cancer 2022;164:80-7. [PMID: 35182925 DOI: 10.1016/j.ejca.2022.01.009] [Reference Citation Analysis]
83 Hack SP, Verret W, Mulla S, Liu B, Wang Y, Macarulla T, Ren Z, El-Khoueiry AB, Zhu AX. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Ther Adv Med Oncol 2021;13:17588359211036544. [PMID: 34377158 DOI: 10.1177/17588359211036544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Alarabiyat M, Raza SS, Isaac J, Mirza D, Marudanayagam R, Roberts K, Abradelo M, Bartlett DC, Dasari BV, Sutcliffe RP, Chatzizacharias NA. Incidental gallbladder cancer diagnosis confers survival advantage irrespective of tumour stage and characteristics. World J Gastroenterol 2022; 28(18): 1996-2007 [DOI: 10.3748/wjg.v28.i18.1996] [Reference Citation Analysis]
85 Chen Y, Zhang B, Liu C, Cao Y, Lyu C, Qiu M. Clinical efficacy of adjuvant treatments for patients with resected biliary tract cancer: a systematic review and network meta-analysis. BMJ Open 2022;12:e051421. [PMID: 35440445 DOI: 10.1136/bmjopen-2021-051421] [Reference Citation Analysis]
86 Gao H, Tian T, Li S, Zhang Y, Fu X, Zheng X, Liu N, Jiang A, Ren M, Zhang X, Liang X, Ruan Z, Geng Z, Yao Y. Efficacy Analysis of Adjuvant Chemotherapy with Gemcitabine Plus Platinum or S-1 in Biliary Tract Carcinoma: A Multi-Center Retrospective Study. Cancer Manag Res 2021;13:889-98. [PMID: 33542660 DOI: 10.2147/CMAR.S290083] [Reference Citation Analysis]